Business
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ...
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR","length":95,"tagName":"p"},{"type":"text","content":"Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results","length":69,"tagName":"p"},{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the fourth quarter and full year ended December 31, 2024.","length":406,"tagName":"p","attribs":{}},{"type":"text","content":"Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team continued to make significant strides in the fourth quarter to deliver what we believe are the ‘Next Generation' opioid analgesics with both abuse and overdose protection. We received feedback from the FDA on our PF614 phase 3 study design and are now taking steps to prepare for the expected start of enrollment of this clinical study in the second quarter of 2025. We are finalizing the selection of clinical sites and an experienced team to execute our PF614 phase 3 trial to remain on track to submit our PF614 New Drug Application in 2026."","length":638,"tagName":"p","attribs":{}},{"type":"text","content":"Dr. Kirkpatrick continued, "Additionally, we are pleased with the continued positive results from our PF614-MPAR-102 study, showing PF614-MPAR provides overdose protection across our planned dosage range, when a greater-than-prescribed dose is consumed at one time. This second study of our overdose protection MPAR technology is continuing to evaluate subjects at higher dose limits in part 1 of the three-part study. The clinical trial is supported by our multi-year award from the National Institute on Drug Abuse and will continue to enroll subjects for parts 2 and 3 over the next year. Furthermore, in January, we entered into a highly valuable strategic partnership for the manufacture and commercial launch of both our PF614 and PF614-MPAR drug products.","length":767,"tagName":"p","attribs":{}},{"type":"text","content":"I'm pleased that Ensysce concluded 2024 and entered 2025 in a very favorab...